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are associated with presence of a CpG island methylator phenotype 
(CIMP), codeletions of the chromosomal arms 1p and 19q (1p/19q), 
and epigenetic silencing of the O6-methylguanine-DNA methyl-
transferase (MGMT) gene that are determined routinely in many brain 
tumor centers due to their diagnostic, prognostic, or predictive value.  
MGMT is frequently silenced by promoter methylation and was found 
to be predictive in glioblastoma for benefit from the addition of the 
alkylating agent therapy temozolomide to radiotherapy, the current 
standard of care. A predictive value was recently confirmed in two 
trials treating elderly glioblastoma patients with either temozolomide 
or radiotherapy. This had a practice changing impact and requires now 
MGMT testing for treatment decision. However, in anaplastic glioma 
MGMT methylation has been reported from two clinical trials to be 
only prognostic. This puzzling result suggested that the molecular 
context of MGMT methylation may be different between these glioma 
subtypes. Indeed, the genetic and epigenetic context is strikingly 
different. In glioblastoma loss of one copy of chromosome 10 on which 
MGMT resides (CHR 10q23) is very frequent (>80%) as opposed to 
anaplastic glioma. Interestingly, in low grade and anaplastic glioma 
MGMT mutations are highly associated with CIMP. Mutations in IDH 
have been found to be an early event, very common in low grade and 
anaplastic glioma (50-80%), while they are infrequent in glioblastoma 
(<10%), usually associated with secondary glioblastoma that evolve 
through evolution of lower grade precursor lesions. Recent 
publications provided evidence that IDH1/2 mutations indirectly, 
through production of an onco-metabolite lead to epigenetic 
deregulation resulting in CIMP. Hence the epigenetic and genetic 
context of MGMT methylation in glioblastoma is different from 
anaplastic glioma. Emphasizing that IDH mutant/CIMP positive gliomas 
are patho-genetically distinct entities with different biological and 
clinical features that respond differently to treatment approaches. 
These insights need to be taken into consideration for future trial 
design.Co-deletions of 1p/19q are usually associated with IDH 
mutations, hence oligodendroglial tumors seem to be a favorable 
subgroup of CIMP associated glioma. Retrospective analysis of two 
clinical trials for anaplastic glioma suggested that 1p/19q co-deletions 
are predictive for benefit from the early addition of chemotherapy to 
radiotherapy a practice changing finding. 
Among the many signatures and molecular markers identified in 
glioma actionable markers are, unfortunately, rare with the currently 
available treatments. New strategies have to be adopted to test 
promising drugs in molecularly stratified patient populations.  
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Current goals of drug design in oncology are to discover and target 
therapies to specific receptors or antigens on tumors, while 
simultaneously avoiding systemic toxicity. Even the targeted therapies 
on the market have notable systemic toxicities, as many of the targets 
are not unique to tumors. Solid tumors contain a unique micro-
environment that is often not conducive to drug distribution. Drugs 
often reach tumor sites by penetrating across the endothelial linings 
of the capillaries, but different pressure gradients inside the tumor 
influence the ability of drugs to extravasate.  
One of the unique aspects of using X-ray radiation therapy (XRT) for 
treating tumors is that it can be delivered to a focused tissue volume. 
This allows for the deposition of high cumulative radiation doses at 
the tumor site while sparing the normal surrounding tissues. New 
research done in the last decade has shown that XRT, although also 
therapeutic, can induce neoantigens at the cell surface of tumors and 
tumor blood vessels. The usefulness of neoantigens for therapeutic 
applications lies in the fact that they are differentially expressed on 
the surface of irradiated tumor cells to a greater extent than on 
normal tissues. This differential expression provides a mechanism by 
which tumor cells can be “marked” by radiation for further targeting. 
Using phage display biopanning, recombinant peptides that bind 
preferentially to radiation-treated cancers have been found. Drug 
delivery vehicles conjugated to ligands that recognize and interact 
with the neoantigens can help to improve tumor-specific targeting and 
potentially reduce systemic toxicity with cancer drugs.  
For instance, our group has found that glucose regulated protein 78 
(GRP78) is present in low levels in normal tissue, shows increased 
expression in numerous solid tumors, and is upregulated after 
treatment with XRT, providing a tumor-specific target for drug 
delivery. The targeting peptide specifically binds to GRP78 post-XRT 
and not normal tissue which allows for an increased percentage of 
drug load to be directly delivered to the radiation-treated tumor 
volume. By using radiation treatment as a means to “mark” the tumor 
for drug delivery, this new potential form of treatment hopes to 
dramatically reduce the systemic toxicity that is typically associated 
with cancer drugs, while simultaneously increasing the biodistribution 
of these drugs to the tumor region. 
In addition to active targeting, alternative methods for tumor-toxic 
payloads have been created, which capitalize on radiation-induced 
targets. XRT has been shown to improve the delivery of nanoparticles 
to tumor cells because it transiently increases the permeability and 
retention effect of the vasculature after single treatments at 
clinically-relevant doses. Another strategy is the use of adenoviruses 
whose transfection rates increase in the presence of ionizing 
radiation. This same technology has led to the creation of the product 
TNFerade, in which TNF-alpha is produced by a radiation-inducible 
promoter but predominantly within the radiation field. This product 
has been successfully tested in phase III clinical trials. 
The characteristics of ionizing radiation that make it an appealing 
option targeting nanoparticles are multiple. First, it is already 
ubiquitously used in cancer treatment protocols. Second, when used 
at low doses for short periods of time, radiation therapy is associated 
with relatively few side effects. Third, it readily penetrates tissue. 
Fourth, it can be accurately delivered to specific tumor volumes while 
sparing surrounding normal tissues. Fifth, it induces site-specific gene 
transcription and protein expression within cancer. Finally, tumor 
targeting peptides are being discovered that bind to radiation-
inducible receptors; these peptides can be functionalized with 
nanoparticle carriers to enable radiation-guided delivery of 
chemotherapy to the tumor microvasculature. Further research 
exploring these targets for therapeutic purposes as well as in the 
discovery of novel radiation-induced antigens will aid in improving 
targeted strategies and the efficacy of radiotherapy. 
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Image guided drug delivery requires physical energy that is deposited 
within cancer to activate drug delivery. The classic example is boron 
neutron capture. More recently, heat has been used to “melt” 
liposomes for thermal control of drug delivery. Ionizing radiation is 
also used to induce the expression of receptors and antigens for 
targeted drug delivery. Magnetic fields are used to guide drug delivery 
and oscillate magnetic nanoparticles to heat tumors. Radiation 
oncologists are uniquely trained in the field of image guided delivery 
of therapy. ESTRO and ASTRO should develop each of these forms of 
external administration of energy to control drug delivery. Although 
these strategies are complementary, they vary in their feasibility to 
bring drug delivery systems into clinical trials and in their cancer 
specificity. Each strategy has its limitations. For example, radiation 
inducible neoantigens and receptors are not induced in every cancer 
subtype. Magnetic fields are site specific but not cancer specific 
which could lead to drug delivery throughout the entire magnetic 
field. Similarly, heat is site specific but not cancer specific and could 
result in drug delivery to adjacent normal tissues. Moreover, the 
thermal regulated liposomes can release the drug systemically. 
Pharmacokinetics of each of these forms of image guided drug 
delivery vary. For example, thermal regulated drug delivery produces 
